[FG] Schaub Stefan

Papachristou, Androniki et al. (2025) ‘Terminal renal failure as a contributor to high-sensitivity cardiac troponin T elevations: Insights from patients undergoing renal transplantation’, Heart. 06.03.2025, 111(17), pp. 835–841. Available at: https://doi.org/10.1136/heartjnl-2024-324686.

Böhmig, G.A. et al. (2025) ‘Antibody-mediated rejection - treatment standard’, Nephrology Dialysis Transplantation, 40. Available at: https://doi.org/10.1093/ndt/gfaf097.

Krättli, J. et al. (2025) ‘Metabolic risk after living kidney donation: an analysis of the Swiss Organ Living-Donor Health Registry’, Swiss Medical Weekly, 155(6), p. 4513. Available at: https://doi.org/10.57187/s.4513.

Diebold, Matthias et al. (2025) ‘Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies’, Nature Medicine, 31(5), pp. 1668–1676. Available at: https://doi.org/10.1038/s41591-025-03653-3.

Diebold, Matthias et al. (2025) ‘Functional Natural Killer-cell Genetics and Microvascular Inflammation After Kidney Transplantation: An Observational Cohort Study’, Transplantation, 109(5), pp. 860–870. Available at: https://doi.org/10.1097/tp.0000000000005228.

Lombardi, Yannis et al. (2025) ‘Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system’, American Journal of Transplantation, 25(5), pp. 1130–1132. Available at: https://doi.org/10.1016/j.ajt.2024.12.004.

Diebold, Matthias et al. (2025) ‘Chronic Rejection After Kidney Transplantation’, Transplantation, 109(4), pp. 610–621. Available at: https://doi.org/10.1097/tp.0000000000005187.

Diebold, Matthias and Sharif, Adnan (2025) ‘Breaking barriers: giving HOPE to people living with HIV and end-stage renal disease’, Clinical Kidney Journal [Preprint]. Available at: https://doi.org/10.1093/ckj/sfaf027.

Mayer, Katharina A. et al. (2025) ‘Targeting CD38 in Antibody-Mediated Rejection’, Transplant International, 38. Available at: https://doi.org/10.3389/ti.2025.14343.

Mayer, Katharina A. et al. (2025) ‘CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation’, Expert Opinion on Investigational Drugs, 34(1-2), pp. 1–10. Available at: https://doi.org/10.1080/13543784.2025.2463092.

Jäger, Cäcilia et al. (2024) ‘Combined Molecular Mismatch Approaches to Predict Immunological Events Within the First Year After Renal Transplantation’, HLA, 104(5). Available at: https://doi.org/10.1111/tan.15748.

Brügger, Charlotte et al. (2024) ‘Early Complications in Kidney Donors and Course of Health-related Quality of Life 12 mo After Donation: An Analysis of the Swiss Organ Living-Donor Health Registry’, Transplantation Direct, 10(11), p. e1716. Available at: https://doi.org/10.1097/txd.0000000000001716.

Halloran, P. et al. (2024) ‘Effect of felzartamab anti-CD38 treatment on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.’ Springer Science and Business Media LLC. Available at: https://doi.org/10.21203/rs.3.rs-4870641/v1.

Schrezenmeier, Eva et al. (2024) ‘A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection’, New England Journal of Medicine, 391(2), pp. 122–132. Available at: https://doi.org/10.1056/nejmoa2400763.

Diebold, Matthias et al. (2024) ‘Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammation’, American Journal of Transplantation, 24(5), pp. 743–754. Available at: https://doi.org/10.1016/j.ajt.2023.12.005.

Hirt-Minkowski, P. and Schaub, S. (2024) ‘Urine CXCL10 as a biomarker in kidney transplantation’, Current Opinion in Organ Transplantation, 29(2), pp. 138–143. Available at: https://doi.org/10.1097/mot.0000000000001135.

Böhmig, Georg A., Diebold, Matthias and Budde, Klemens (2024) ‘Opinions on the Future of Clinical Pig Kidney Xenotransplantation’, Transplant International, 37. Available at: https://doi.org/10.3389/ti.2024.13475.

Diebold, Matthias et al. (2024) ‘Natural Killer Cell Presence in Antibody-Mediated Rejection’, Transplant International , 37. Available at: https://doi.org/10.3389/ti.2024.13209.

Simonavicius, Justas et al. (2024) ‘Diagnostic and prognostic utility of bone morphogenetic protein 10 in acute dyspnea: a cohort study’, Clinical Research in Cardiology [Preprint]. Available at: https://doi.org/10.1007/s00392-024-02584-2.

Hirt-Minkowski, Patricia, Wehmeier, Caroline and Schaub, Stefan (2023) ‘Authors” Reply: Of End Points and Context of Use: A Reasonable Silver Lining for Urinary Chemokines Monitoring’, Journal of the American Society of Nephrology, 34(10), pp. 1766–1767. Available at: https://doi.org/10.1681/asn.0000000000000205.

Hug, Melanie N. et al. (2023) ‘HLA antibody affinity determination: From HLA-specific monoclonal antibodies to donor HLA specific antibodies (DSA) in patient serum’, HLA, 102(3), pp. 278–300. Available at: https://doi.org/10.1111/tan.15047.

Ho, Julie et al. (2023) ‘Multicenter Validation of a Urine CXCL10 Assay for Noninvasive Monitoring of Renal Transplants’, Transplantation, 107(7), pp. 1630–1641. Available at: https://doi.org/10.1097/tp.0000000000004554.

Schwab, S. et al. (2023) ‘Clinical prediction model for prognosis in kidney transplant recipients (KIDMO): study protocol’, Diagnostic and Prognostic Research, 7(1). Available at: https://doi.org/10.1186/s41512-022-00139-5.

de Rougemont, Olivier et al. (2023) ‘Donation type and the effect of pre-transplant donor specific antibodies – Data from the Swiss Transplant Cohort Study’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1104371.

Schreiber, P.W. et al. (2022) ‘Surgical site infections after simultaneous pancreas kidney and pancreas transplantation in the Swiss Transplant Cohort Study’, Journal of Hospital Infection, 128, pp. 47–53. Available at: https://doi.org/10.1016/j.jhin.2022.07.009.

Frischknecht, Lukas et al. (2022) ‘The impact of pre-transplant donor specific antibodies on the outcome of kidney transplantation – Data from the Swiss transplant cohort study’, Frontiers in Immunology, 13. Available at: https://doi.org/10.3389/fimmu.2022.1005790.

Dirchwolf, M. et al. (2022) ‘The MELD upgrade exception: a successful strategy to optimize access to liver transplantation for patients with high waiting list mortality’, HPB, 24(7), pp. 1168–1176. Available at: https://doi.org/10.1016/j.hpb.2021.12.009.

Bräutigam M et al. (2022) ‘Frequency, reactivity and evolution of human leukocyte antigen and human platelet antigen antibodies in the setting of hematopoietic cell transplantation’, Transfusion and Apheresis Science, 61(2), p. 103301. Available at: https://doi.org/10.1016/j.transci.2021.103301.

Kuhn C. et al. (2022) ‘Relevance of deceased donor proteinuria for kidney transplantation: A comprehensive national cohort study’, Clinical Transplantation, 36(4). Available at: https://doi.org/10.1111/ctr.14574.

Niemann M et al. (2021) ‘Peptides Derived From Mismatched Paternal Human Leukocyte Antigen Predicted to Be Presented by HLA-DRB1, -DRB3/4/5, -DQ, and -DP Induce Child-Specific Antibodies in Pregnant Women’, Frontiers in Immunology, 12, p. 797360. Available at: https://doi.org/10.3389/fimmu.2021.797360.

Wehmeier, Caroline et al. (2021) ‘Pre-transplant donor-specific HLA antibodies and risk for poor first-year renal transplant outcomes: results from the Swiss Transplant Cohort Study’, Transplant International, 34(12), pp. 2755–2768. Available at: https://doi.org/10.1111/tri.14119.

Julen K. et al. (2021) ‘Transfusions in Aplastic Anemia Patients Cause HLA Alloimmunization: Comparisons of Current and Past Cohorts Demonstrate Progress’, Transplantation and Cellular Therapy, 27(11), p. 939.e1–939.e8. Available at: https://doi.org/10.1016/j.jtct.2021.07.017.

Ingold L. et al. (2021) ‘Short- and long-term impact of neutropenia within the first year after kidney transplantation’, Transplant International, 34(10), pp. 1875–1885. Available at: https://doi.org/10.1111/tri.13976.

Schweiger, M. et al. (2021) ‘Use of induction therapy in pediatric heart transplant recipients in Switzerland – Analysis of the Swiss national database’, Transplant Immunology, 68. Available at: https://doi.org/10.1016/j.trim.2021.101443.

Handschin J et al. (2021) ‘Urinary CXCL10 Measurement in Late Renal Allograft Biopsies Predicts Outcome Even in Histologically Quiescent Patients’, Transplantation Proceedings, 53(7), pp. 2168–2179. Available at: https://doi.org/10.1016/j.transproceed.2021.07.013.

Senn L et al. (2021) ‘Outcome of Husband-to-Wife Kidney Transplantation With Mutual Children: Single Center Experience Using T Cell-Depleting Induction and Review of the Literature’, Frontiers in Medicine, 8, p. 724851. Available at: https://doi.org/10.3389/fmed.2021.724851.

Diebold M et al. (2021) ‘Temporal trends of COVID-19 related in-hospital mortality and demographics in Switzerland - a retrospective single centre cohort study’, Swiss Medical Weekly, 151(29-30), p. w20572. Available at: https://doi.org/10.4414/smw.2021.20572.

Diebold M et al. (2021) ‘Comparison of acute kidney injury in patients with covid-19 and other respiratory infections: A prospective cohort study’, Journal of Clinical Medicine, 10(11). Available at: https://doi.org/10.3390/jcm10112288.

Kuhn C. et al. (2021) ‘Outcome of kidney transplantation from very senior donors in Switzerland – a national cohort study’, Transplant International, 34(4), pp. 689–699. Available at: https://doi.org/10.1111/tri.13836.

Perrottet N et al. (2021) ‘Infectious complications and graft outcome following treatment of acute antibodymediated rejection after kidney transplantation: A nationwide cohort study’, PLoS ONE, 16(4 April), p. e0250829. Available at: https://doi.org/10.1371/journal.pone.0250829.

Diebold M et al. (2021) ‘Acute kidney injury in patients with COVID-19: A retrospective cohort study from Switzerland’, Swiss Medical Weekly, 151(9), p. w20482. Available at: https://doi.org/10.4414/smw.2021.20482.

Cun H et al. (2021) ‘Screening strategy for de novo donor-specific HLA antibodies beyond the first year after kidney transplantation: Personalized or “one size fits all”?’, Clinical Transplantation, 35(2), p. e14170. Available at: https://doi.org/10.1111/ctr.14170.

Bonani M et al. (2021) ‘Dialysis after graft loss: A Swiss experience’, Nephrology Dialysis Transplantation, 35(12), pp. 2182–2190. Available at: https://doi.org/10.1093/ndt/gfaa037.

Schawalder L et al. (2021) ‘Development of an immunogenicity score for HLA-DQ eplets: A conceptual study’, HLA, 97(1), pp. 30–43. Available at: https://doi.org/10.1111/tan.14110.

Stampf, Susanne et al. (2021) ‘Cohort profile: The Swiss Transplant Cohort Study (STCS): A nationwide longitudinal cohort study of all solid organ recipients in Switzerland’, BMJ Open, 11(12), p. e051176. Available at: https://doi.org/10.1136/bmjopen-2021-051176.

Hönger G et al. (2020) ‘Toward defining the immunogenicity of HLA epitopes: Impact of HLA class I eplets on antibody formation during pregnancy’, HLA, 96(5), pp. 589–600. Available at: https://doi.org/10.1111/tan.14054.

Bischof N et al. (2020) ‘Revisiting cytomegalovirus serostatus and replication as risk factors for inferior long-term outcomes in the current era of renal transplantation’, Nephrology Dialysis Transplantation, 35(2), pp. 346–356. Available at: https://doi.org/10.1093/ndt/gfz268.

Handschin J et al. (2020) ‘Technical Considerations and Confounders for Urine CXCL10 Chemokine Measurement’, Transplantation Direct, 6(1), p. e519. Available at: https://doi.org/10.1097/txd.0000000000000959.

Wehmeier, Caroline et al. (2020) ‘Donor-specific B Cell Memory in Alloimmunized Kidney Transplant Recipients: First Clinical Application of a Novel Method’, Transplantation, 104(5), pp. 1026–1032. Available at: https://doi.org/10.1097/tp.0000000000002909.

Wehmeier C, Hönger G and Schaub S (2020) ‘Caveats of HLA antibody detection by solid-phase assays’, Transplant International, 33(1), pp. 18–29. Available at: https://doi.org/10.1111/tri.13484.

Leuzinger K. et al. (2019) ‘Quantification of plasma BK polyomavirus loads is affected by sequence variability, amplicon length, and non-encapsidated viral DNA genome fragments’, Journal of Clinical Virology, 121. Available at: https://doi.org/10.1016/j.jcv.2019.104210.

Spica D et al. (2019) ‘Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation’, Case Reports in Nephrology and Dialysis. S. Karger AG, 9(3). Available at: https://doi.org/10.1159/000503951.

Bischof N et al. (2019) ‘Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation: Long-term outcomes’, Nephrology Dialysis Transplantation, 34(7), pp. 1240–1250. Available at: https://doi.org/10.1093/ndt/gfy346.

Schaub S, Immer F and Steiger J (2019) ‘Organ Transplantation in Switzerland’, Transplantation, 103(5), pp. 853–855. Available at: https://doi.org/10.1097/tp.0000000000002565.

Ersözlü S et al. (2018) ‘Long-term Outcomes of Kidney Transplantation in Fabry Disease’, Transplantation, 102(11), pp. 1924–1933. Available at: https://doi.org/10.1097/tp.0000000000002252.

Naegele K et al. (2018) ‘Cytomegalovirus sequence variability, amplicon length, and DNase-sensitive non-encapsidated genomes are obstacles to standardization and commutability of plasma viral load results’, Journal of Clinical Virology, 104, pp. 39–47. Available at: https://doi.org/10.1016/j.jcv.2018.04.013.

Arnold ML et al. (2018) ‘Anti-HLA alloantibodies of the IgA isotype in re-transplant candidates part II: Correlation with graft survival’, International Journal of Immunogenetics. 25.03.2018, 45(3), pp. 95–101. Available at: https://doi.org/10.1111/iji.12363.

Bouquegneau A et al. (2018) ‘Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis’, PLoS Medicine, 15(5), p. e1002572. Available at: https://doi.org/10.1371/journal.pmed.1002572.

Ho J et al. (2018) ‘Urinary CXCL10 Chemokine Is Associated with Alloimmune and Virus Compartment-Specific Renal Allograft Inflammation’, Transplantation, 102(3), pp. 521–529. Available at: https://doi.org/10.1097/tp.0000000000001931.

Wehmeier C et al. (2018) ‘Successful steroid withdrawal guided by surveillance biopsies—A single-center experience’, Clinical Transplantation, 32(3), p. e13181. Available at: https://doi.org/10.1111/ctr.13181.

Nickeleit V et al. (2018) ‘The Banff Working Group Classification of Definitive Polyomavirus Nephropathy: Morphologic Definitions and Clinical Correlations’, Journal of the American Society of Nephrology, 29(2), pp. 680–693. Available at: https://doi.org/10.1681/asn.2017050477.

Valenzuela NM and Schaub S (2018) ‘The biology of IgG subclasses and their clinical relevance to transplantation’, Transplantation, 102(1S), pp. S7–S13. Available at: https://doi.org/10.1097/tp.0000000000001816.

Hönger G et al. (2017) ‘Effects of weak/non-complement-binding HLA antibodies on C1q-binding’, HLA. 05.06.2017, 90(2), pp. 88–94. Available at: https://doi.org/10.1111/tan.13062.

Wehmeier C et al. (2017) ‘Donor Specificity but Not Broadness of Sensitization Is Associated With Antibody-Mediated Rejection and Graft Loss in Renal Allograft Recipients’, American Journal of Transplantation, 17(8), pp. 2092–2102. Available at: https://doi.org/10.1111/ajt.14247.

Reiher, Viktoria S A et al. (2017) ‘Human platelet antigen antibody induction in uncomplicated pregnancy is associated with HLA sensitization’, Transfusion. Blackwell Publishing Inc., 57(5). Available at: https://doi.org/10.1111/trf.14053.

Hirsch, H. et al. (2017) ‘BK Polyomavirus-Specific 9mer T-Cell Responses Predict Control of Viremia in Kidney Transplant Recipients: First Report from the Swiss Transplant Cohort Study’. WILEY, 17.

Wehmeier C et al. (2017) ‘Acute Rejection Phenotypes in the Current Era of Immunosuppression: A Single-Center Analysis’, Transplantation Direct, 3(3), p. e136. Available at: https://doi.org/10.1097/txd.0000000000000650.

Kim MJ et al. (2016) ‘Effect of immunosuppressive drugs on the changes of serum galactose-deficient IgA1 in patients with IgA nephropathy’, PLoS ONE, 11(12). Available at: https://doi.org/10.1371/journal.pone.0166830.

Duquesnoy RJ et al. (2016) ‘Antibody-defined epitopes on HLA-DQ alleles reacting with antibodies induced during pregnancy and the design of a DQ eplet map’, Human Immunology, 77(10), pp. 824–831. Available at: https://doi.org/10.1016/j.humimm.2016.06.021.

Hirt-Minkowski P et al. (2016) ‘Six-month urinary CCL2 and CXCL10 levels predict long-term renal allograft outcome’, Transplantation, 100(9), pp. 1988–1996. Available at: https://doi.org/10.1097/tp.0000000000001304.

Duquesnoy RJ et al. (2016) ‘Detection of newly antibody-defined epitopes on HLA class I alleles reacting with antibodies induced during pregnancy’, International Journal of Immunogenetics. 16.06.2016, 43(4), pp. 200–208. Available at: https://doi.org/10.1111/iji.12280.

Duquesnoy RJ et al. (2016) ‘Identification of epitopes on HLA-DRB alleles reacting with antibodies in sera from women sensitized during pregnancy’, Human Immunology, 77(2), pp. 214–222. Available at: https://doi.org/10.1016/j.humimm.2015.12.002.

Burkhalter, F. et al. (2016) ‘A Comparison of Two Types of Rabbit Antithymocyte Globulin Induction Therapy in Immunological High-Risk Kidney Recipients: A Prospective Randomized Control Study’, PLoS ONE, 11(11), p. e0165233. Available at: https://doi.org/10.1371/journal.pone.0165233.

Drexler, Beatrice et al. (2016) ‘Impact of donor ABH-secretor status in ABO-mismatched living donor kidney transplantation’, Transfusion, 56(9), pp. 61–2355. Available at: https://doi.org/10.1111/trf.13711.

Geneugelijk K et al. (2016) ‘A previous miscarriage and a previous successful pregnancy have a different impact on HLA antibody formation during a subsequent successful pregnancy’, Frontiers in Immunology, 7(DEC), p. 571. Available at: https://doi.org/10.3389/fimmu.2016.00571.

Geneugelijk K et al. (2015) ‘Predicted indirectly recognizable HLA epitopes presented by HLA-DRB1 are related to HLA antibody formation during pregnancy’, American Journal of Transplantation. 29.10.2015, 15(12), pp. 3112–3122. Available at: https://doi.org/10.1111/ajt.13508.

Hirt-Minkowski P et al. (2015) ‘Prediction of Long-term Renal Allograft Outcome by Early Urinary CXCL10 Chemokine Levels’, Transplantation Direct. 24.09.2015, 1(8), p. e31. Available at: https://doi.org/10.1097/txd.0000000000000537.

Amico P and Schaub S (2015) ‘Donor-specific HLA-antibodies: The difficulty of separating the wheat from the chaff’, American Journal of Transplantation. Blackwell Publishing Ltd, 15(4). Available at: https://doi.org/10.1111/ajt.13156.

Burger, Bettina et al. (2015) ‘Risk of Cutaneous Squamous Cell Carcinoma Development in Renal Transplant Recipients Is Independent of TMC/EVER Alterations’, Dermatology, 231(3), pp. 52–245. Available at: https://doi.org/10.1159/000435910.

Egli, A. et al. (2015) ‘Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) directly from positive blood culture flasks allows rapid identification of bloodstream infections in immunosuppressed hosts’, Transpl Infect Dis, 17(3), pp. 7–481. Available at: https://doi.org/10.1111/tid.12373.

Hönger, G. et al. (2015) ‘Inter-individual differences in HLA expression can impact the CDC crossmatch’, Tissue Antigens, 85(4), pp. 6–260. Available at: https://doi.org/10.1111/tan.12537.

Hönger G et al. (2014) ‘Human pregnancy and generation of anti-angiotensin receptor and anti-perlecan antibodies’, Transplant International, 27(5), pp. 467–474. Available at: https://doi.org/10.1111/tri.12282.

Schaub S et al. (2014) ‘Determinants of C1q binding in the single antigen bead assay’, Transplantation, 98(4), pp. 387–393. Available at: https://doi.org/10.1097/tp.0000000000000203.

Praehauser C et al. (2013) ‘Risk factors and outcome of expanded-criteria donor kidney transplants in patients with low immunological risk’, Swiss Medical Weekly. 12.11.2013, 143, p. w13883. Available at: https://doi.org/10.4414/smw.2013.13883.

Suesal, C. et al. (2013) ‘Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients’, Tissue Antigens, 82(2), pp. 83–92. Available at: https://doi.org/10.1111/tan.12137.

Hönger G et al. (2013) ‘Frequency and determinants of pregnancy-induced child-specific sensitization’, American Journal of Transplantation. 11.01.2013, 13(3), pp. 746–753. Available at: https://doi.org/10.1111/ajt.12048.

Arnold ML et al. (2013) ‘16th IHIW: Anti-HLA alloantibodies of the of IgA isotype in re-transplant candidates’, International Journal of Immunogenetics. 22.12.2012, 40(1), pp. 17–20. Available at: https://doi.org/10.1111/iji.12032.

Hirt-Minkowski P et al. (2013) ‘Soluble CD30 correlates with clinical but not subclinical renal allograft rejection’, Transplant International. 08.11.2012, 26(1), pp. 75–83. Available at: https://doi.org/10.1111/j.1432-2277.2012.01578.x.

Menter, T. et al. (2013) ‘Pathology of Resolving Polyomavirus-Associated Nephropathy’, American journal of transplantation, 13(6), pp. 1474–1483. Available at: https://doi.org/10.1111/ajt.12218.

Schaub S and Hirt-Minkowski P (2013) ‘Urinary-cell mRNA and acute kidney-transplant rejection [1]’, New England Journal of Medicine, 369(19), pp. 1858–1861. Available at: https://doi.org/10.1056/nejmc1310006.

Hirt-Minkowski P et al. (2012) ‘Delayed graft function is not associated with an increased incidence of renal allograft rejection’, Clinical Transplantation. 29.10.2012, 26(6), pp. E624–33. Available at: https://doi.org/10.1111/ctr.12041.

Hirt-Minkowski P et al. (2012) ‘Detection of clinical and subclinical tubulo-interstitial inflammation by the urinary CXCL10 chemokine in a real-life setting’, American Journal of Transplantation, 12(7), pp. 1811–1823. Available at: https://doi.org/10.1111/j.1600-6143.2012.03999.x.

Burkhalter F, Schaub S and Dickenmann M (2012) ‘Preserved circannual rhythm of vitamin D in kidney transplant patients’, Swiss Medical Weekly. 04.09.2012, 142, p. w13672. Available at: https://doi.org/10.4414/smw.2012.13672.

Amico, Patrizia et al. (2011) ‘Risk stratification by the virtual crossmatch : a prospective study in 233 renal transplantations’, Transplant international, 24(6), pp. 9–560. Available at: https://doi.org/10.1111/j.1432-2277.2011.01235.x.

Bray, R. A., Murphey, C. and Schaub, S. (2011) ‘Calculated PRA : a process whose time has come or “Déjà vu” all over again?’, American journal of transplantation, 11(4), pp. 650–651. Available at: https://doi.org/10.1111/j.1600-6143.2011.03452.x.

Durovic, B et al. (2011) ‘Allo-induced acute-phase response : IL-6 identifies a subset of individuals at risk for graft injury’, Scandinavian journal of immunology, 73(2), pp. 8–156. Available at: https://doi.org/10.1111/j.1365-3083.2010.02489.x.

Hönger, Gideon et al. (2011) ‘Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection’, Transplantation, 92(1), pp. 7–41. Available at: https://doi.org/10.1097/tp.0b013e31821cdf0d.

Bächler, K et al. (2010) ‘Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies’, American journal of transplantation, 10(5), pp. 62–1254. Available at: https://doi.org/10.1111/j.1600-6143.2010.03093.x.

Hönger, Gideon et al. (2010) ‘C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection’, Transplantation, 89(12), pp. 5–1471. Available at: https://doi.org/10.1097/tp.0b013e3181dc13e7.

Schaub, S et al. (2010) ‘Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy’, American journal of transplantation, 10(12), pp. 23–2615. Available at: https://doi.org/10.1111/j.1600-6143.2010.03310.x.